Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
August 19, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...
Statement on the Passing of Rev. James Lawson
June 11, 2024 06:00 ET
|
National Civil Rights Museum
Memphis, TN, June 11, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum is deeply saddened by the passing of civil rights philosopher and strategist, Rev. James M. Lawson, Jr. ...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
April 08, 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Small Cell Lung Cancer Therapeutics Market Value to Exceed of USD 12.9 Bn by 2031, rising at a 11.9% CAGR: TMR Report
May 05, 2023 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global small cell lung cancer therapeutics market was valued at USD 4.6 Bn in 2022 and is projected to expand at a CAGR of...
Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight
April 14, 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, April 14, 2022 (GLOBE NEWSWIRE) -- Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Small-cell Lung Cancer Pipeline...
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
August 17, 2021 09:25 ET
|
Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
August 03, 2021 09:25 ET
|
Lixte Biotechnology Holdings, Inc.
A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently...
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
May 04, 2021 16:30 ET
|
Lixte Biotechnology Holdings, Inc.
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE...
"The Church Is Not The Building, The Church is The People," Proclaimed 4 Prominent Delaware Church Leaders
April 12, 2020 01:59 ET
|
360Wise Media
MIAMI, April 12, 2020 (GLOBE NEWSWIRE) -- “As Pastors, we need to take the health of our community seriously, particularly our most vulnerable to this virus,” says Reverend Tracy Mooney, Pastor of...
"A 53 Billion Dollar Federal Reserve Infusion Is What a Downpayment on White Reparation Looks Like," Says Robert Alexander President Of The Miami SCLC
September 27, 2019 06:09 ET
|
360Wise Media
MIAMI, Sept. 27, 2019 (GLOBE NEWSWIRE) -- "We bring this to your attention to point out the Fed's abysmal record on helping black banks and bankers. Since 1994 when there were 55 black-owned banks,...